Open Access

Exercise-induced bronchoconstriction: new evidence in pathogenesis, diagnosis and treatment

Asthma Research and Practice20151:2

DOI: 10.1186/s40733-015-0004-4

Received: 12 December 2014

Accepted: 7 May 2015

Published: 2 July 2015

Abstract

The acute airway narrowing that occurs as a result of exercise is defined exercise-induced bronchoconstriction (EIB). Most recent guidelines recommend distinguishing EIB with underlying clinical asthma (EIBA) from the occurrence of bronchial obstruction in subjects without other symptoms and signs of asthma (EIBwA). EIB has been in fact reported in up to 90 % of asthmatic patients, reflecting the level of disease control, but it may develop even in subjects without clinical asthma, particularly in children, athletes, patients with atopy or rhinitis and following respiratory infections. Both EIBA and EIBwA have peculiar pathogenic mechanisms, diagnostic criteria and responses to treatment and prevention. The use of biomarkers, proteomic approaches and innovative technological procedures will hopefully contribute to better define peculiar phenotypes and to clarify the role of EIB as risk factor for the development of asthma, as well as an occupational disease.

Keywords

Exercise Bonchoconstriction Asthma Athlete Sport Doping Phenotypes Biomarkers Beta-2 agonist

Review

Introduction

The term exercise-induced bronchoconstriction (EIB) describes the acute airway narrowing that occurs as a result of exercise [1]. It has long been known that physical exercise may trigger symptoms of asthma. However, the interest for an objective study on this phenomenon may be dated back to 50 years ago, when Jones and co-workers focused on the physiologic response to exercise in asthmatic children and named the airway obstruction after an exercise challenge exercise-induced asthma (EIA) [2]. Subsequent research defined the different patterns of response to exercise in asthmatic patients, the effect of type, intensity and duration of challenges, and the influence of anti-asthmatic drugs on EIA.

In reviewing these studies, Godfrey concluded that, despite of “some exceptions, there has been no evidence that EIA occurs in patients other than asthmatics, and although sporadic cases have been reported where exercise appears to have been the only precipitant of asthma in a patient (usually an adult), careful investigation has usually revealed other clinical and physiological manifestations of bronchial asthma” [3].

Although some authors consider EIA as a distinct asthma phenotype [4], it is quite evident that exercise may trigger bronchial obstruction and clinical symptoms in almost all asthmatic patients, independently from the causes and mechanisms of the underlying asthma. In fact, the prevalence of EIA has been reported in up to 90 % of asthmatic patients, reflecting the level of disease control, with EIA occurring more frequently in more severe and uncontrolled asthmatic patients [5].

However, the concept that exercise may induce bronchial obstruction in asthmatic patients only is in question [6]. Exercise-induced bronchoconstriction (EIB) may in fact develop even in subjects without clinical asthma. This is particularly true in children, athletes, and patients with atopy or rhinitis, or following respiratory infections [7-10]. It is not easy, however, to report prevalence rates in these populations because they also depend on the type and intensity of exercise, as well as the environmental conditions in which the challenge is performed. Certainly, EIB that occurs in athletes without clinical asthma has peculiar clinical and pathologic features [11] and often disappears after discontinuation of intense training [12].

To bring some clarity to this still controversial issue, a Practice Parameter, jointly developed by the American Academy/College of Allergy Asthma and Immunology (AAAAI/ACAAI) [13], and more recently an American Thoracic Society Clinical Practice Guideline [14], recommended to abandon the term of EIA (because exercise is not the cause, but only a trigger of asthma) and to name EIB with asthma (EIBA), the occurrence of bronchial obstruction after exercise in asthmatic patients, and EIB without asthma (EIBwA), the occurrence of bronchial obstruction in subjects without other symptoms and signs of clinical asthma.

Pathogenesis

EIB was initially thought to be secondary to a mediator release from mast cells [3]. This hypothesis was also supported by the refractory period observed after a positive exercise challenge, interpreted as the time needed for mast cell recharge, and by the preventive effect offered by mast cell stabilizing agents, such as sodium cromoglycate. Although mediator release does contribute to cause EIB, pathophysiologic changes induced by intense exercising are definitely more complex. At present, it is widely accepted that hyperventilation through the mouth associated with intense exercise causes the need for humidifying and heating large volumes of air during a short period of time. Elegant experiments performed by S.D. Anderson and coworkers [15] show that the respiratory water loss and the increase in osmolarity of the airways surface liquid represent the major determinants of EIB (osmotic theory). In fact, the dryer and cooler is the inspired air and the higher is the ventilation, the greater is the likelihood of a positive response to exercise, which also explains the higher prevalence of EIB in winter sport disciplines [16]. The vasodilation associated with airways rewarming (thermal theory) may also play a role in inducing bronchial obstruction after exercise [17].

In EIBA, the previously mentioned mechanisms only represent a trigger of the underlying airway hyperreactivity in subjects with different phenotypes of asthma not under control.

However, in EIBwA, the epithelial damage of a large number of bronchial tree divisions down to peripheral airways represents the predominant pathogenic mechanism [18]. A direct effect of viral infections, occupational agents and exercise may in fact represent a causal mechanism of bronchoconstriction, alternative to the classic eosinophilic mast cell–dependent pathway occurring in allergic asthma [19]. The role of epithelial damage and of substances released by the epithelium and found in sputum, such as interleukin-8 and leukotrienes [20, 21], and in serum or urines, such as Nerve Growth Factor (NGF) and the Clara cell protein CC16 [20, 22], may also explain the heterogeneous inflammatory response reported in EIBwA [23]. The increase of columnar epithelial cells in induced sputum [20] is, in fact, associated with a neutrophilic or mixed eosinophilic–neutrophilic inflammation [24, 25]. The importance of aquaporin, expressed by the subepithelial glandular cells, in regulating the water transport through the epithelium [26], as well as the increased mucus production, as shown by the increased expression of MUC5AC in induced sputum [27], may be also relevant in EIBwA.

At last, autonomic dysregulation may also have a role in causing bronchial obstruction in EIBwA [28], both through the basal increased parasympathetic tone shown in athletes and through reflex mechanisms induced by exercise.

Diagnosis

Research performed over the past twenty years in athletes has consistently revealed a poor relationship between the presence of ‘asthma-like’ symptoms and objective evidence of EIB [29, 30]. Furthermore, pulmonary function tests at baseline appear to be poorly predictive of EIB in athletes, often being within the normal ranges even in the presence of disease [31]. Thus, in order to establish a secure diagnosis of EIB it is important to perform objective testing to confirm dynamic changes in airway function [14].

Bronchoprovocative tests (BPTs)

After a careful history and physical examination, measuring the change in the forced expiratory volume in the 1 s (FEV1) before and after a standardized exercise challenge test (ECT), in the laboratory or in the field, represents the most intuitive and commonly adopted approach to diagnose EIB [32]. An ECT should be performed in subjects with EIBA only when their baseline FEV1 is ≥70 % of normal.

A ≥10 % fall in FEV1 at any two consecutive time-point recordings (1, 3, 5, 10, 15, 20, 25, 30 min.) after 6 to 8 min of treadmill or cycloergometer exercise in ambient conditions (20-25 °C; relative humidity <50 %), is considered diagnostic of EIB [32]. The intensity of exercise should be enough to reach in the first 2–3 min. 40-60 % of the predicted maximum voluntary ventilation (estimated as baseline FEV1 X 35) or 80-90 % of the predicted maximal heart rate (calculated by 220 - age). Indeed, it has been reported that the mean fall in FEV1 after an exercise challenge is more than doubled after achieving 95 % of HR max, compared to 85 % [33]. Standard criteria for laboratory exercise testing may be insufficient to induce a positive response in highly trained individuals and may fail to properly reproduce the bronchoprovocative stimulus experienced by athletes practicing their own sport discipline. Accordingly, sports-specific challenges are also used in athletes. However, these are more difficult to standardize, limiting their application.

Other BPTs may be adopted as surrogate diagnostic tools for EIB. Direct BPTs, (i.e. methacholine and histamine provocation), are accurate to document bronchial hyperreactivity in asthma and in EIBA, while indirect tests, such as eucapnic voluntary hyperpnea, hypertonic saline challenge, and mannitol inhaled powder challenge, better reproduce the effects of exercise on the airways and are therefore more accurate to diagnose EIBwA [34]. Though, correlations between exercise tests and other indirect BPTs are at present arguable and vary from test to test [35].

The International Olympic Committee recommends specific thresholds for the various BPTs to document asthma or EIB and to permit the use of anti-asthmatic drugs that are banned or limited by the World Anti-Doping Agency (Table 1).
Table 1

International Olympic Committee criteria for the diagnosis of asthma and permission to use of beta-2 agonists: a positive clinical history associated to at least one positive test is required

Diagnostic procedure

Criteria

Pulmonary function

FEV1 < 70 %, FEV1/VC <55 %

Bronchodilator test

↑ FEV1 ≥ 12 % or >200 ml

Eucapnic Voluntary Hyperpnea (EVH)

↓ FEV1 ≥ 10 %

Exercise challenge

↓ FEV1 ≥ 10 %

Methacholine challenge

↓ FEV1 ≥ 20 % with a:

PC20 ≤ 4 mg/ml (for subjects not taking ICS)

or

PC20 ≤ 16 mg/ml (for subjects taking ICS for at

least 1 month)

Hyperosmolar test (Mannitol, Saline)

↓ FEV1 ≥ 15 %

The differential diagnosis of EIB should take into account physiologic limitations; anxiety; exercise-induced laryngeal dysfunctions, hyperventilation and hypoxemia; dyspnoea on exertion in obese or poorly fit individuals; shortness of breath with exercise due to lung diseases (other than asthma), cardiac diseases; anemia; myopathies [14].

In particular, vocal cord dysfunction and structural glottis abnormalities are increasingly recognized as conditions that may mimic EIB [36]. However, in vocal cord dysfunction, inspiratory stridor during exercise usually resolves within 5 min representing the major differential sign, associated with negative BPT result and poor response to anti-asthmatic drugs. Vocal cord dysfunction may also coexist with EIB.

If pruritus, urticaria or systemic reactions are associated with symptoms of EIB, the diagnosis of exercise-induced urticaria or anaphylaxis should be at last considered [37].

Treatment and Prevention

Treatment of both EIBA and EIBwA is essentially based on reversing bronchial obstruction by using short-acting beta-2 agonists [5].

Pharmacologic Prevention

Several pharmacologic approaches can be adopted to prevent EIB [38]. Because EIBA is a sign of poor asthma control, prevention essentially consists of following international guidelines to achieve asthma control [5]. The potential occurrence of EIBA should not prevent asthmatic patients from an adequate practice of physical exercise, which is not associated to an increased risk of asthma developing or worsening and should instead represent part of their treatment [39]. Multiple therapeutic options may be also appropriate to prevent EIBwA, although usually they do not completely avoid the occurrence of bronchoconstriction, but rather attenuate it or shift the dose–response relationship, so that some submaximal efforts become tolerated. Special precautions must be however taken with respect to the World Anti-Doping Agency (WADA) rules on the use of medications for EIBA and EIBwA in competitive athletes (Table 2).
Table 2

Most frequently used medications for EIBA and EIBwA and the 2015 World Anti-Doping Agency (WADA) regulations

Treatment

WADA rules

Notes

Antihistamines

Permitted

Second generation molecules should be preferred to avoid side effects

Leukotriene modifiers

Permitted

 

Inhaled steroids

Permitted

 

Systemic steroids

Prohibited in competition

 

Beta-2 agonists

Inhaled Salbutamol (max 1600 mcg/24H), Formoterol (max 54 mcg/24H) and Salmeterol permitted

The presence in urine of salbutamol >1000 ng/mL or formoterol >40 ng/mL is presumed not to be an intended therapeutic use of the substance and will be considered as an Adverse Analytical Finding

All others prohibited in and out

 

competition

 

Mast-cell stabilizers

Permitted

 

Anticholinergic agents

Permitted

 

Immunotherapy

Permitted

SCIT should not be performed before or after physical exercise

Mast cell stabilizers (not available in all countries), disodium cromoglycate and nedocromil sodium, attenuate both EIBA and EIBwA when inhaled shortly before exercise, but only have a short duration of action [40].

Leukotriene antagonists (i.e. montelukast) have been reported to be effective in preventing EIBA [41]. However, protection may not be complete and occurs in approximately 50 % of subjects [42].

Regular use of inhaled corticosteroid (ICS) represents the therapy of choice for asthma control and therefore is a recommended treatment to prevent EIBA [43]. The prophylactic administration of ICS has been also suggested in EIBwA, particularly if physical activity is performed regularly (>3 times per week), representing a repetitive stimulus for the onset of bronchoconstriction [13]. However, the use of ICS in the prevention of EIBwA may be controversial. In fact this pharmacological strategy is at present not supported by ad-hoc designed clinical trials and response to treatment may be impaired in subjects with an underlying neutrophilic inflammatory pattern.

Beta-2 adrenergic drugs, both short- and long-acting (SABA and LABA), when given in a single inhaled dose or with intermittent administration before exercise, are the most effective drugs to prevent both EIBA and EIBwA [44], providing complete protection against exercise (FEV1 fall <10 %) in 68 % of subjects [45]. The effect usually lasts 2 to 4 h for SABA and up to 12 h for LABA. Heterogeneity observed in the efficacy of beta-2 adrenergic agents to prevent EIB is not dependent on the type of molecule used, but rather on the population sample studied, with more variable effects reported in children [46].

However, the chronic use of SABA and LABA often results in a reduction of the duration and/or magnitude of protection against EIB with cross-reacting tolerance to other beta-2 agonists [45, 47]. This loss of efficacy seems to be only partially prevented by ICS [48]. Furthermore, daily use of SABA and LABA may also result in a worsening of EIB [49]. Therefore, SABA and LABA should be used with caution on a daily basis to prevent EIB. At last, LABA administration should be avoided without concomitant use of ICS according to the U.S. Food and Drug Administration (FDA) warning [50].

Ipratropium bromide prevents EIBA, although this effect is not consistent among patients and may be variable in the same patient [51]. Whether subjects with EIBwA or with a prevalent autonomic imbalance represent an EIB phenotype more responsive to anticholinergic agents represents an interesting hypothesis, still waiting for further experimental testing [52].

Calcium channel blockers, beta-adrenergic receptor antagonists, inhaled furosemide, heparin, and hyaluronic acid have been studied to prevent EIB with inconsistent results [13].

Non-Pharmacologic Prevention

Similar non-pharmacologic preventive measures can be adopted in both EIBA and EIBwA [13]. These include, whenever possible, avoiding exercise in an at-risk air environment because of temperature, humidity, and pollutants or specific allergens in sensitized subjects. Gradual warming-up and cooling-down periods are always suggested. Some athletes also take advantage of the refractory period after bronchial obstruction deliberately induced by hyperventilation or by an intense exercise challenge. The use of face masks which warm and humidify the air has been reported to provide benefits. There is at last some evidence that weight loss and dietary factors, such as a low sodium intake, omega-3 polyunsaturated fatty acids, or a supplementation of ascorbic acid may be helpful in reducing the occurrence and severity of EIB [53].

Conclusions and Perspectives

Hyperventilation associated with exercise may induce bronchial obstruction in asthmatic patients. However, using the term EIA to define a specific asthma phenotype does not seem appropriate because exercise is only a trigger of a symptom common to all etiologic forms of asthma not under control. EIB may also occur in subjects without clinical asthma. Both EIBA and EIBwA have peculiar pathogenic mechanisms, diagnostic criteria and responses to treatment and prevention. Further research investigations are desirable to better understand relationships and differences between EIBA and EIBwA and to definitely affirm if they represent two different phenotypes. With this regards it is suggested to adopt a scientific approach which includes the use of biomarkers, proteomics and innovative technological procedures [54-57]. Moreover, it should be interesting to assess whether children with EIBwA are at higher risk for developing clinical asthma with age. At last, it should be questioned if EIB in athletes should be considered an occupational disease due to repeated exercising in inadequate environmental conditions [58].

Declarations

Acknowledgements

None

Authors’ Affiliations

(1)
Department of Public Health and Infectious Diseases, “Sapienza” University of Rome

References

  1. Anderson SD. Exercise-induced asthma. In: Kay AB, editor. Allergy and Allergic Disease. Oxford: Blackwell Scientific Publications; 1997. p. 692–711.Google Scholar
  2. Jones KS, Buston MH, Wharton MJ. The effect of exercise on ventilator function in the child with asthma. Br J Dis Chest. 1962;56:78–86.View ArticlePubMedGoogle Scholar
  3. Godfrey S. Exercise-induced asthma. In: Clark TJH, Godfrey S, editors. Asthma. London: Chapman and Hall; 1977. p. 57–8.Google Scholar
  4. Wenzel SE. Asthma: defining the persistent asthma phenotypes. Lancet. 2006;368:804–13.View ArticlePubMedGoogle Scholar
  5. 2014 Global Initiative for Asthma. Global Strategy for Asthma and Management and Prevention. National Institutes of Health, Lung and Blood Institute, World Health Organization workshop report. Bethesda, Md; Medical Communication Resources; Available from: http://www.ginasthma.org.
  6. Bonini S. EIB or not EIB? That is the question. Med Sci Sports Exerc. 2008;40(9):1565–6.View ArticlePubMedGoogle Scholar
  7. Randolph C. Exercise-induced bronchospasm in children. Clin Rev Allergy Immunol. 2008;34(2):205–16.View ArticlePubMedGoogle Scholar
  8. Carlsen KH, Anderson SD, Bjermer L, Bonini S, Brusasco V, Canonica W, et al. Exercise-induced asthma, respiratory and allergic disorders in elite athletes: epidemiology, mechanisms and diagnosis: part I of the report from the Joint Task Force of the European Respiratory Society (ERS) and the European Academy of Allergy and Clinical Immunology (EAACI) in cooperation with GA2LEN. Allergy. 2008;63(4):387–403.View ArticlePubMedGoogle Scholar
  9. Bonini M, Bachert C, Baena-Cagnani CE, Bedbrook A, Brozek JL, Canonica GW, et al. What we should learn from the London Olympics. ARIA Initiative, in collaboration with the WHO Collaborating Center for Asthma, Rhinitis. Curr Opin Allergy Clin Immunol. 2013;13(1):1–3.View ArticlePubMedGoogle Scholar
  10. Sandrock CE1, Norris A. Infection in Severe Asthma Exacerbations and Critical Asthma Syndrome. Clin Rev Allergy Immunol. 2014 Jul 2. [Epub ahead of print]Google Scholar
  11. Parsons JP, Mastronarde JG. Exercise-induced bronchoconstriction in athletes. Chest. 2005;128(6):3966–74.View ArticlePubMedGoogle Scholar
  12. Helenius I, Rytilä P, Sarna S, Lumme A, Helenius M, Remes V, et al. Effect of continuing or finishing high-level sports on airway inflammation, bronchial hyperresponsiveness, and asthma: a 5-year prospective follow-up study of 42 highly trained swimmers. J Allergy Clin Immunol. 2002;109:962–8.View ArticlePubMedGoogle Scholar
  13. Weiler JM, Anderson SD, Randolph C, Bonini S, Craig TJ, Pearlman DS, et al. Pathogenesis, prevalence, diagnosis, and management of exercise-induced bronchoconstriction: a practice parameter. Ann Allergy Asthma Immunol. 2010;105:S1–S47.View ArticlePubMedGoogle Scholar
  14. Parsons JP, Hallstrand TS, Mastronarde JG, Kaminsky DA, Rundell KW, Hull JH, et al. An official American Thoracic Society clinical practice guideline: exercise-induced bronchoconstriction. Am J Respir Crit Care Med. 2013;187(9):1016–27.View ArticlePubMedGoogle Scholar
  15. Anderson SD, Daviskas E. The mechanism of exercise-induced asthma is …. J Allergy Clin Immunol. 2000;106:453–9.View ArticlePubMedGoogle Scholar
  16. Rundell KW, Spiering BA, Evans TM, Baumann JM. Baseline lung function, exercise-induced bronchoconstriction, and asthma-like symptoms in elite women ice hockey players. Med Sci Sports Exerc. 2004;36:405–10.View ArticlePubMedGoogle Scholar
  17. McFadden ER. Hypothesis: exercise-induced asthma as a vascular phenomenon. Lancet. 1990;1:880–3.View ArticleGoogle Scholar
  18. Anderson SD, Kippelen P. Airway injury as a mechanism for exercise-induced bronchoconstriction in elite athletes. J Allergy Clin Immunol. 2008;122:225–35.View ArticlePubMedGoogle Scholar
  19. Holgate ST. Epithelial dysfunction in asthma. J Allergy Clin Immunol. 2007;120:1233–44.View ArticlePubMedGoogle Scholar
  20. Chimenti L, Morici G, Paternò A, Santagata R, Bonanno A, Profita M, et al. Bronchial epithelial damage after a half-marathon in nonasthmatic amateur runners. Am J Physiol Lung Cell Mol Physiol. 2010;298:L857–862.Google Scholar
  21. Hallstrand TS. New insights into pathogenesis of exercise-induced bronchoconstriction. Curr Opin Allergy Clin Immunol. 2012;12:42–8.View ArticlePubMedPubMed CentralGoogle Scholar
  22. Romberg K, Bjermer L, Tufvesson E. Exercise but not mannitol increases urinary Clara cell protein (CC16) in elite swimmers. Respir Med. 2011;105:31–6.View ArticlePubMedGoogle Scholar
  23. Bonini M, Fioretti D, Sargentini V, Del Giacco S, Rinaldi M, Tranquilli C, et al. Increased nerve growth factor serum levels in top athletes. Clin J Sport Med. 2013;23(3):228–31.Google Scholar
  24. Karjalainen E-M, Laitinen A, Sue-Chu M, Altraja A, Bjermer L, Laitinen LA. Evidence of airway inflammation and remodeling in ski athletes with and without bronchial hyperresponsiveness to methacholine. Am J Respir Crit Care Med. 2000;161:2086–91.View ArticlePubMedGoogle Scholar
  25. Bougault V, Loubaki L, Joubert P, Turmel J, Couture C, Laviolette M, et al. Airway remodeling and inflammation in competitive swimmers training in indoor chlorinated swimming pools. J Allergy Clin Immunol. 2012;129:351–8.Google Scholar
  26. Moreira A, Delgado L, Carlsen K-H. Exercise-induced asthma: why is it so frequent in Olympic athletes? Expert Rev Respir Med. 2011;5:1–3.View ArticlePubMedGoogle Scholar
  27. Hallstrand TS, Debley JS, Farin FM, Henderson Jr WR. Role of MUC5AC in the pathogenesis of exercise-induced bronchoconstriction. J Allergy Clin Immunol. 2007;119:1092–8.View ArticlePubMedPubMed CentralGoogle Scholar
  28. Filipe JA, Falcao-Reis S, Castro-Correia J, Barros H. Assessment of autonomic function in high level athletes by pupillometry. Auton Neurosci. 2003;104:66–72.View ArticlePubMedGoogle Scholar
  29. Ansley L, Kippelen P, Dickinson J, Hull JH. Misdiagnosis of exercise-induced bronchoconstriction in professional soccer players. Allergy. 2012;67(3):390–5.View ArticlePubMedGoogle Scholar
  30. Dickinson JW, Whyte GP, McConnell AK, Harries MG. Impact of changes in the IOC-MC asthma criteria: a British perspective. Thorax. 2005;60(8):629–32.View ArticlePubMedPubMed CentralGoogle Scholar
  31. Bonini M, Lapucci G, Petrelli G, Todaro A, Pamich T, Rasi G, et al. Predictive value of allergy and pulmonary function tests for the diagnosis of asthma in elite athletes. Allergy. 2007;62(10):1166–70.View ArticlePubMedGoogle Scholar
  32. Crapo RO, Casaburi R, Coates AL, Enright PL, Hankinson JL, Irvin CG, et al. ATS Guidelines for methacholine and exercise challenge testing 1999. Am J Respir Crit Care Med. 2000;161:309–29.View ArticlePubMedGoogle Scholar
  33. Carlsen KH, Engh G, Mørk M. Exercise-induced bronchoconstriction depends on exercise load. Respir Med. 2000;94(8):750–5.View ArticlePubMedGoogle Scholar
  34. Rundell KW, Slee JB. Exercise and other indirect challenges to demonstrate asthma or exercise-induced bronchoconstriction in athletes. J Allergy Clin Immunol. 2008;122:238–46.View ArticlePubMedGoogle Scholar
  35. Stickland MK, Rowe BH, Spooner CH, Vandermeer B, Dryden DM. Accuracy of eucapnic hyperpnea or mannitol to diagnose exercise-induced bronchoconstriction: a systematic review. Ann Allergy Asthma Immunol. 2011;107(3):229–34.e8.View ArticlePubMedGoogle Scholar
  36. Nielsen EW, Hull JH, Backer V. High prevalence of exercise-induced laryngeal obstruction in athletes. Med Sci Sports Exerc. 2013;45(11):2030–5.View ArticlePubMedGoogle Scholar
  37. Bonini M, Palange P. Anaphylaxis and sport. Curr Opin Allergy Clin Immunol. 2014;14(4):323–7.View ArticlePubMedGoogle Scholar
  38. Carlsen KH, Anderson SD, Bjermer L, Bonini S, Brusasco V, Canonica W, et al. Treatment of exercise-induced asthma, respiratory and allergic disorders in sports and the relationship to doping. Part II of the report from the Joint Task Force of European Respiratory Society (ERS) and European Academy of Allergy and Clinical Immunology (EAACI) in cooperation with GA (2) LEN. Allergy. 2008;63:492–505.View ArticlePubMedGoogle Scholar
  39. Ventura MT, Cannone A, Sinesi D, Buquicchio R, Carbonara M, Di Leo E, et al. Sensitization, asthma and allergic disease in young soccer players. Allergy. 2009;64(4):556–9.View ArticlePubMedGoogle Scholar
  40. Spooner CH, Spooner GR, Rowe BH. Mast-cell stabilizing agents to prevent exercise-induced bronchoconstriction. Cochrane Database Syst Rev. 2003;4, CD002307.Google Scholar
  41. Leff JA, Busse WW, Pearlman D, Bronsky EA, Kemp J, Hendeles L, et al. Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction. N Engl J Med. 1998;339:147–52.View ArticlePubMedGoogle Scholar
  42. Pearlman DS, van Adelsberg J, Philip G, Tilles SA, Busse W, Hendeles L, et al. Onset and duration of protection against exercise-induced bronchoconstriction by a single oral dose of montelukast. Ann Allergy Asthma Immunol. 2006;97:98–104.View ArticlePubMedGoogle Scholar
  43. Koh MS, Tee A, Lasserson TJ, Irving LB. Inhaled corticosteroids compared to placebo for prevention of exercise induced bronchoconstriction. Cochrane Database Syst Rev. 2007;3, CD002739.Google Scholar
  44. Anderson SD, Caillaud C, Brannan JD. Beta2-agonists and exercise-induced asthma. Clin Rev Allergy Immunol. 2006;31:163–80.View ArticlePubMedGoogle Scholar
  45. Bonini M, Di Mambro C, Calderon MA, Compalati E, Schünemann H, Durham S, et al. Beta-2 agonists for exercise-induced asthma. Cochrane Database Syst Rev. 2013;10:CD003564.Google Scholar
  46. Bonini M. Beta-2 agonists for exercise-induced bronchoconstriction in children. Paediatr Respir Rev. 2014;15(1):42–4.PubMedGoogle Scholar
  47. Bonini M, Permaul P, Kulkarni T, Kazani S, Segal A, Sorkness CA, et al. Loss of salmeterol bronchoprotection against exercise in relation to ADRB2 Arg16Gly polymorphism and exhaled nitric oxide. Am J Respir Crit Care Med. 2013;188(12):1407–12.Google Scholar
  48. Salpeter SR, Ormiston TM, Salpeter EE. Meta-analysis: respiratory tolerance to regular beta2-agonist use in patients with asthma. Ann Intern Med. 2004;140:802–13.View ArticlePubMedGoogle Scholar
  49. Hancox RJ, Subbarao P, Kamada D, Watson RM, Hargreave FE, Inman MD. Beta2-agonist tolerance and exercise-induced bronchospasm. Am J Respir Crit Care Med. 2002;165(8):1068–70.View ArticlePubMedGoogle Scholar
  50. US Food and Drug Administration. www.fda.gov Accessed on November 20, 2014
  51. Boaventura LC, Araujo AC, Martinez JB, Vianna EO. Effects of ipratropium on exercise-induced bronchospasm. Int J Sports Med. 2010;31(7):516–20. doi:10.1055/s-0030-1249624. Epub 2010 May 12.View ArticlePubMedGoogle Scholar
  52. Couto M, Silva D, Santos P, et al. Exploratory study comparing dysautonomia between asthmatic and non-asthmatic elite swimmers. Rev Port Pneumol. 2014. [Epub ahead of print]Google Scholar
  53. Moreira A, Bonini M, Garcia-Larsen V, Bonini S, Del Giacco SR, Agache I, et al. Weight loss interventions in asthma: EAACI evidence-based clinical practice guideline (part I). Allergy. 2013;68(4):425–39.Google Scholar
  54. ElHalawani SM, Ly NT, Mahon RT, Amundson DE. Exhaled nitric oxide as a predictor of exercise-induced bronchoconstriction. Chest. 2003;124(2):639–43.Google Scholar
  55. Zietkowski Z, Skiepko R, Tomasiak-Lozowska MM. RANTES in exhaled breath condensate of allergic asthma patients with exercise-induced bronchoconstriction. Respiration. 2010;80(6):463–71.View ArticlePubMedGoogle Scholar
  56. Hilberg T. Etiology of exercise-induced asthma: physical stress-induced transcription. Curr Allergy Asthma Rep. 2007;7(1):27–32.View ArticlePubMedGoogle Scholar
  57. Bonini M, Marcomini L, Gramiccioni C. Microarray evaluation of specific IgE to allergen components in elite athletes. Allergy. 2012;67(12):1557–64.PubMedGoogle Scholar
  58. Price OJ, Ansley L, Menzies-Gow A, Cullinan P, Hull JH. Airway dysfunction in elite athletes–an occupational lung disease? Allergy. 2013;68(11):1343–52.Google Scholar

Copyright

© Bonini and Palange; licensee BioMed Central. 2016

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement